Cerba - comment

With the majority of the debt locked up, we expect limited price action following the Q2 results and conference call. Management confirmed that Cerba has filed to enter court-supervised Conciliation, following the mandat ad hoc process that has been ongoing since April. The court is expected to open the process within the next couple of weeks, providing a more formal framework for negotiations with lenders and bondholders. The existing waiver has extended the grace period for the unpaid June/August interest until 30 November, giving stakeholders time to reach an agreement. The process can run for up to five months, although the key issue remains unchanged: with €4.9bn of net debt and 8.0x senior secured leverage, a restructuring of the capital structure will be required irrespective of the tariff outcome or operating performance.

French tariffs remain the more important near-term catalyst. Technical discussions with CNAM began at the end of August, with a further meeting scheduled for 28 September that could potentially finalise a new agreement. CNAM has presented three scenarios for the biology spending envelope: ~0.6% growth in the low case, 1.6–1.75% in the central case and ~3.5% in the high case. Assuming underlying volume growth of 3.5–4%, this implies roughly 0–3% annual price cuts, with the central case pointing to c.2% price declines. Management effectively acknowledged that this is the range currently under consideration, although negotiations remain ongoing. Parliament will debate the Social Security budget from mid-October and could still introduce additional measures, including a potential profit cap. A favourable tariff agreement by September would nevertheless remove a significant source of uncertainty ahead of the restructuring negotiations.

The Q2 results were better than expected, although of limited credit significance. Revenue increased 2.3% to €469m, and EBITDA reached €122m, lifting the margin to 26.0%. Excluding Research, revenue grew 4.3%, while H1 operating cash flow reached €155m versus €107m. Research remains weak on reported revenue, but bookings increased 43% YoY to €42m, with 1.3x book-to-bill. Overall, the results provide some comfort on underlying trading and cash generation, but do not materially alter the restructuring equation.